The 2022 Tandem Meetings | CD30, a promising target for CAR-T therapy in Hodgkin lymphoma
Natalie Grover, MD, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, discusses the potential of CD30 as a target for CAR-T therapy in Hodgkin lymphoma (HL). CD30 is universally expressed in HL and has limited expression in healthy tissues, and clinical trials have reported high response rates with low rates of toxicity in heavily pre-treated patients. However, the durability of response to CD30-directed CAR-T therapy is still relatively low. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Transcript (edited for clarity)
So CD30 is universally expressed in Hodgkin Lymphoma and has minimal expression in normal tissue, which makes it a really promising target for CAR-Ts. Previous clinical trials have shown that CD30-directed CAR-Ts have high response rates in patients with Hodgkin Lymphoma. Even patients who have been refractory to multiple lines of therapy, including brentuximab vedotin and checkpoint inhibitors...
So CD30 is universally expressed in Hodgkin Lymphoma and has minimal expression in normal tissue, which makes it a really promising target for CAR-Ts. Previous clinical trials have shown that CD30-directed CAR-Ts have high response rates in patients with Hodgkin Lymphoma. Even patients who have been refractory to multiple lines of therapy, including brentuximab vedotin and checkpoint inhibitors. So, CD30 CAR-Ts are very promising target for Hodgkin Lymphoma and can treat patients with really refractory disease.
The main challenges now are that we have really high response rates, but a lot of patients still relapse, with the majority of patients still relapsing at one year. So we still need to improve the durability of responses. And of course, there’s also some patients who are not responding to CD30 CAR-Ts. So this is a really promising treatment, which has low toxicity, very tolerable for patients with low cytokine release syndrome and no neurotoxicity, but we still need to improve on the durability of responses for these patients.
Read more...
Disclosures
Consulting with Tessa Therapeutics.
